Gene regulatory architecture of CD56 bright natural killer cells
Gene regulatory architecture of CD56 bright natural killer cells
批准号:
10377919
负责人:
Patrick Leonard Collins
金额:
$19.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2024-03-31
关键词:
Activities of Daily LivingAcute Myelocytic LeukemiaAdoptedAdoptive Cell TransfersAntibodiesArchitectureAutomobile DrivingBiological AssayBiological ModelsBloodBone MarrowCell Differentiation processCell TherapyCell physiologyCellsChronicClinicalComputational algorithmCytokine ReceptorsDataData SetDevelopmentEnhancersEnvironmentEpigenetic ProcessEpithelialEpitope MappingExploratory/Developmental GrantGenerationsGenetic TranscriptionGenomicsGoalsHematologic NeoplasmsHeterogeneityHumanImmuneImmune responseImmunityIn VitroInfectionInfection ControlInflammationInflammation MediatorsInflammatoryInterferon Type IIInvadedLabelLogicLymphLymphocyteLymphoid CellMalignant NeoplasmsMeasurementMediatingMediator of activation proteinMolecularMucous MembraneMusNCAM1 geneNK cell therapyNatural Killer CellsNatureNeoplasm MetastasisOutputPathologyPathway interactionsPhenotypePopulationPopulation HeterogeneityProcessProductionRegulator GenesResearchResearch PersonnelResidenciesResourcesSentinelSignal TransductionSolid NeoplasmStimulusTestingTherapeuticTissuesTonsilTransforming Growth Factor betaXenograft procedureanti-cancercancer immunotherapeuticscytokinecytokine therapycytotoxiccytotoxicitydesignepigenomeexperimental studygraft vs host diseaseimmunoreactioninflammatory milieuinterestintraepithelialkiller factorlymph nodesmultidimensional datanovelpreventreceptorself-renewaltissue repairtumor
中文摘要
项目总结
这个项目的重点是基因组调节器如何引导自然杀伤(NK)细胞控制感染和
恶性肿瘤。在这方面,具体目标是:1)确定循环和组织-
像NK细胞这样的常驻“助手”在表观上相互重塑;以及,2)确定调控转换点
这种“锁定”循环中的NK细胞进入他们的细胞溶解谱系,阻止辅助身份。
自然杀伤细胞是天生的淋巴细胞,这意味着它们可以识别并通常消除感染。
和肿瘤,然后才需要产生全面的免疫反应。这种与生俱来的功能使它们
尤其可用于新一代疗法:NK细胞不能参与移植物抗宿主病
(对细胞治疗很重要),它们可以配备抗体(抗体介导的治疗所需),
并对环境做出快速反应(对细胞因子疗法很重要)。考虑到他们在小说中的承诺
癌症和免疫治疗,对临床有益的NK细胞表型有更深入的了解
优先考虑。
不幸的是,慢性炎症可能会阻止NK细胞在用于治疗时发挥作用。因此,
这项提案的目标是定义炎症环境如何通过表观遗传学建立NK细胞身份
编程。首先,我们将研究慢性炎症如何改变NK细胞表观基因组,使其关闭
NK细胞在治疗中的有益特性。然后我们将分析炎症过程中NK细胞的异质性,
包括它们的表观遗传景观。输出将作为公开可用的数据集提供,理想情况下
被许多研究人员用来确定控制杀手NK细胞身份的机制。事实上,随着这个过程
可能在不同的病理学中功能失调,但这些数据可能对广泛的领域感兴趣。许多
感染、实体肿瘤和血液系统恶性肿瘤,如急性髓系白血病,创造了环境
对NK细胞进行重新编程。因此,已识别的途径可能是有效免疫的主要障碍。
英文摘要
PROJECT SUMMARY
This project focuses on how genomic regulators direct natural killer (NK) cells to control infections and
malignancies. In this regard, the specific aims are: 1) to determine mechanisms by which circulating and tissue-
resident “helper” like NK cells epigenetically remodel into each other; and, 2) identify regulatory transition points
that “lock” circulating NK cells into their cytolytic lineage, blocking the helper identities.
Natural killer cells are innate lymphocytes, which means they can recognize, and normally eliminate, infections
and tumors before a full immune response needs to be generated. This innate functionality makes them
particularly exploitable for a new generation of therapies: NK cells cannot participate in graft-versus-host disease
(important for cellular therapy), they can be armed with antibodies (required for antibody-mediated therapies),
and rapidly respond to their environment (important for cytokine therapies). Given their promise in novel anti-
cancer and immune therapeutics, a deeper understanding of clinically beneficial NK cell phenotypes is of high
priority.
Unfortunately, chronic inflammation may prevent NK cells from functioning when exploited for therapies. As such,
the goal of this proposal is to define how inflammatory environments establish NK cell identities, via epigenetic
programming. First, We will investigate how chronic inflammation alters the NK cell epigenome, shutting down
the beneficial features of NK cells used in therapy. We will then assay NK cell heterogeneity during inflammation,
including their epigenetic landscape. The output will be made available as publicly available datasets, ideally
used by many researchers to identify mechanisms governing killer NK cell identities. Indeed, as this process
may be dysfunctional in diverse pathologies, the data could be of interest to a wide range of fields. Many
infections, solid tumors and hematological malignancies, such as acute myeloid leukemia, create environments
that reprogram NK cells. Thus, the identified pathways may be a major barrier to effective immunity.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1128/mbio.03391-22
发表时间:
2023-04-25
期刊:
mBio
影响因子:
6.4
作者:
[]
通讯作者:
DOI:
10.3390/cancers15030705
发表时间:
2023-01-24
期刊:
Cancers
影响因子:
5.2
作者:
[]
通讯作者:
DOI:
10.1146/annurev-immunol-101320-025949
发表时间:
2022-04-26
期刊:
Annual review of immunology
影响因子:
29.7
作者:
[]
通讯作者:
海外基金